Posts with tag: CRO
Swiss health-care investor HBM Healthcare Investments explores sale of Swixx Biopharma SA, potentially valued at 1.5 billion Swiss francs ($1.7 billion).
Published on: February 21, 2025, 10:01 AM UTC